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Survival post liver transplant for GVHD vs non-GVHD indication
Abstracts / Biol Blood Marrow Transplant 21 (2015) S322eS354 S331rabbit anti-human CD83 antibodies prevented GVHD in
mouse and human preclinical alloHCT models. A second
generation human mAb 3C12C has been evaluated as a novel
therapeutic (Seldon et al, in prep) and its ability to deplete
activated DC and preserve protective T cell responses was
investigated.
Methods: Control human IgG1 (trastazumab) and 3C12C
mAb were tested in human peripheral blood mononuclear
cell (PBMC) cultures and in allogeneic mixed lymphocyte
cultures (alloMLC) for their ability to deplete DC. The anti-
body was tested in a human xenogeneic TBI and anti-NK
conditioned SCID mouse model of GVHD. Survival, clinical
scoring and histology were used to document the effect of
3C12C compared to the control mAb. Flow cytometry and
immunohistology were used to investigate CD83 induction
and the effect of 3C12C on human DC and T cell biology.
Results: 3C12C but not the control mAb reduced the number
of CD83+ DC in PBMC cultures. The 3C12C mAb reduced T cell
proliferation in the alloMLC but did not affect Cytomegalo-
virus speciﬁc CD8+ T cell numbers. Human cells were iden-
tiﬁed in the liver, lung, spleen and gut of the control mAb
treated PBMC transplanted mice, which developed histo-
logical GVHD d+8-13. Human DC were activated by d+2 and
expressed the CMRF-44 activation marker plus CD83, CD80
and CD86. Treatment with 3C12CmAb eliminated CD83+
CMRF44+ DC early post-transplant and reduced T cell acti-
vation in terms of CD25, CD69 and CD137 and cytokine
expression but maintained Treg cells.
Conclusion: A potential therapeutic human anti-CD83 mAb
appears to induce signiﬁcant immunosuppression, associ-
ated with the depletion of CMRF-44+ activated DC, whilst
preserving T cell numbers.481
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Background: Liver graft-versus-host-disease (GVHD) after
hematopoietic stem cell transplantation (HSCT) is uniformly
fatal once it becomes steroid-refractory. No FDA-approved
treatments exist for this condition and majority of the clin-
ical trials in GVHD treatment paradigm have focused on the
general treatment of acute GVHD as a whole rather than
organ speciﬁc treatment. Case reports and case series of
orthotopic liver transplantation (OLT) for hepatic GVHD have
been published with varying results. Herein, we present the
analysis from a large national database on the outcomes of
OLT in hepatic GVHD.
Methods: A United Network for Organ Sharing (UNOS)
database review of all OLTs between 1998 and 2012 was
performed*. Rejection, transplant list registration, blood*“Based on OPTN data as of January 17, 2014; This work was supported in
part by Health Resources and Services Administration contract 234-2005-
37011C. The content is the responsibility of the authors alone and does not
necessarily reﬂect the views or policies of the Department of Health and Hu-
man Services, nor does mention of trade names, commercial products, or or-
ganizations imply endorsement by the U.S. Government.”group type, indications, waiting time, MELD score and
other relevant variables for both HSCT and OLT were
obtained and analyzed for clinical outcomes, using the Cox
proportional hazards model. Survival after OLT performed
for GVHD was compared to OLT performed for non-GVHD
indications.
Results: 112 OLTs were reported by UNOS for GVHD. N was
94 for the ﬁnal sample for analysis given the criteria used for
inclusion in the study. Among these, 46 had hepatic GVHD
secondary to renal or intestinal transplantation, and 48
following HSCT. Median survival for HSCT-GVHD patients
was 8.5 years. 1, 3 and 5 year survival of the HSCT-GVHD
patients were 0.69, 0.64 and 0.59, respectively. ABO
grouping, age, gender, and MELD score did not affect the
patient survival in the HSCT-GVHD cohort. Survival analyses
performed for OLT stratiﬁed by indication (GVHD vs no
GVHD) [ﬁgure 1] indicate signiﬁcant differences in outcome.
Conclusion: OLT is an underutilized treatment modality for
hepatic GVHD in HSCT patients. Although the survival after
OLT for GVHD is inferior to that of OLT for non-GVHD in-
dications, it is remarkably better than non-OLT strategies
currently utilized for treatment of hepatic GVHD (5 year
survival <10%, historic data). Thus, OLT should be considered
early in management of steroid refractory hepatic GVHD.
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Introduction: Milatuzumab is a humanized IgG1K mono-
clonal antibody that interacts with CD74, leading to rapid
internalization and cytotoxicity independent of antibody
crosslinking. CD74, also known as HLA class II invariant
chain, is a cell-surface antigen expressed on antigen pre-
senting cells (APCs) and involved in pro-survival signaling.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S322eS354S332Thus, milatuzumab has potential to inhibit APC-mediated T-
cell proliferation and decrease the risk of aGVHD. In a
xenogeneic SCID mouse model, milatuzumab administered
prior to transplant prevented the development of GVHD,
suppressed circulating cytokines, and reduced the mortality
of the SCID mice (Chen et al, BBMT, 2013).
Methods: We are performing an open-label, single-center
phase 1 dose escalation trial to determine the maximum
tolerated dose (MTD) of milatuzumab when added to stan-
dard GVHD prophylaxis using reduced-intensity condition-
ing (RIC) for HLA matched (8/8) sibling or unrelated SCT.
Patients (pts) are premedicated with dexamethasone and
receive milatuzumab intravenously on days -7, -4, -1, and +7.
The initial starting dose was 8 mg/kg (DL1) with dose esca-
lation to 16 mg/kg (DL2) and 20 mg/kg in cohorts of 3-6 until
unacceptable toxicity. Dose limiting toxicities are deﬁned as
graft failure, any  grade 4 organ toxicities excluding ex-
pected hematologic toxicities from SCT, or grade 4 infusion
reactions attributable to milatuzumab. Acute and chronic
GVHDwas recorded according to Consensus and NIH criteria,
respectively.
Results: Nine pts have been treated with median follow up
of 56 days post transplant (average 121 days; range 13-
294). The median age is 57 years (range 26-70). Pts had a
variety of hematologic malignancies. Median Sorror co-
morbidity score was 1 (range 0-8). Recipients received RIC
with ﬂudarabine (30 mg/m2days -7 through -3) and
busulfan (0.8 mg/kg every 6 hours days -4 and -3 for total
of 8 doses) along with tacrolimus and methotrexate (D+ 1,
3, 6, & 11). Donors were 8/8 HLA-matched siblings or
matched unrelated. All pts received four doses of milatu-
zumab and 3 or 4 doses of methotrexate. Three individuals
were initially treated at DL1 followed by 3 pts at DL2. At
DL2, one pt died from relapsed AML, and 2 pts died from
grade 5 sepsis. At DL2, only one experienced GVHD (grade
4 cutaneous that was indistinguishable from Stevens-
Johnson Syndrome). As a result, three more pts were
enrolled to DL1 to assess safety. Only 1 of 6 pts at DL1 had
toxicity attributable to milatuzumab (grade 1 tremor). InFigure 1. Phosphoﬂow assaDL1, 3 of 6 had aGVHD with 2 of 3 experiencing grade 1 and
one grade 2 cutaneous GVH.
Conclusions: While the grade 5 events in DL2 (16 mg/kg)
were not considered speciﬁcally attributable to milatuzu-
mab, DL1 (8mg/kg) has been well tolerated without any
grade 3 GVHD. We will continue to monitor at DL1 and
pending tolerability may amend the protocol to test an in-
termediate dose of 12 mg/kg. Milatuzumab remains an
intriguing potential agent to prevent aGVHD.483
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Background: Brief CCR5blockadeusingmaraviroc (MVC) after
reduced-intensity alloSCT resulted in a low incidence of acute
GvHD and protection against visceral GvHD. We observed sig-
niﬁcant variability in baseline T-cell CCR5 expression in donors
and recipients. We therefore hypothesized that effective
blockade of CCR5 activation is dependent on its baseline
expression. To test this,wedeveloped aphosphoﬂowassay that
measures the activity of MVC in fresh blood samples.
Methods: The phosphoﬂow assay (Fig. 1) quantiﬁes CCR5
activationbymeasuringphosphorylationof a C-terminal serine
residue (SER349) using a phosphospeciﬁc CCR5 antibody. To
demonstrate activity, CCL4 stimulationwas performed in fresh
whole blood with or without excess MVC. Change in pCCR5
levels was measured as the MFI fold-change from a baseliney for CCR5 activation
